- Relationship between Ulcerative Colitis Patients Treated with Leukocytapheresis and Ulcerative Colitis-associated Colorectal Cancer
[作者:Kinugasa, T; Akagi, Y; Murotani, K; Romeo, K; Yoshida, T; Ryu, Y; Shiratuchi, I; Shirouzu, K,期刊:Anticancer Research, 页码:2547-2552 , 文章类型: Proceedings Paper,,卷期:2011年31-7]
- Background: Leukocytapheresis (LCAP) is a recent modality for treatment of patients with ulcerative colitis (UC). This study aimed to assess whether LCAP changed the development of colorectal cancer (CRC) in patients wit...
- Assessment of HB-EGF Levels in Peritoneal Fluid and Serum of Ovarian Cancer Patients using ELISA
[作者:Hikita, S; Yotsumoto, F; Fumaki, T; Horiuchi, S; Sanui, A; Miyata, K; Nam, SO; Tsujioka, H; Ueda, T; Shirota, K; Yoshizato, T; Maeda, K; Ishikawa, T; Okuno, Y; Kuroki, M; Mekada, E; Miyamoto, S,期刊:Anticancer Research, 页码:2553-2559 , 文章类型: Proceedings Paper,,卷期:2011年31-7]
- Background: Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a rational target for ovarian cancer therapy. The aim of this study was to examine HB-EGF levels in the peritoneal fluid and serum of ova...
- Induction of Cytotoxic T Lymphocytes by CEA Peptide-pulsed gamma delta T-Cells Isolated from Patients with Advanced Cancer
[作者:Yamasaki, A; Onishi, H; Morisaki, T; Katano, M,期刊:Anticancer Research, 页码:2419-2424 , 文章类型: Proceedings Paper,,卷期:2011年31-7]
- Cytotoxic gamma delta T-cells recognize antigens directly without the need for antigen processing and presentation. Recently, it was reported that they can also present antigens and proliferate in vitro. In this study, w...
- Sonodynamic Cancer Therapy: A Non-invasive and Repeatable Approach Using Low-intensity Ultrasound with a Sonosensitizer
[作者:Shibaguchi, H; Tsuru, H; Kuroki, M; Kuroki, M,期刊:Anticancer Research, 页码:2425-2429 , 文章类型: Proceedings Paper,,卷期:2011年31-7]
- The low-intensity ultrasound that is used in clinical diagnoses, such as abdomen echo inspection, is a non-invasive treatment, and penetrates deeper into the body than light. Recently, sonodynamic therapy (SDT), which us...
- WT1 Peptide Vaccine Stabilized Intractable Ovarian Cancer Patient for One Year: A Case Report
[作者:Dohi, S; Ohno, S; Ohno, Y; Takakura, M; Kyo, S; Soma, GI; Sugiyama, H; Inoue, M,期刊:Anticancer Research, 页码:2441-2445 , 文章类型: Proceedings Paper,,卷期:2011年31-7]
- We report on Wilms tumor (WT1) peptide immunotherapy in a patient with intractable ovarian cancer patient over an extended period. Case Report: Immunotherapy using WT1 peptide has been undergoing clinical trials for gyne...
- Frequency of Myeloid Dendritic Cells Can Predict the Efficacy of Wilms' Tumor 1 Peptide Vaccination
[作者:Ohno, S; Takano, F; Ohta, Y; Kyo, S; Myojo, S; Dohi, S; Sugiyama, H; Ohta, T; Inoue, M,期刊:Anticancer Research, 页码:2447-2452 , 文章类型: Proceedings Paper,,卷期:2011年31-7]
- Background: The object of this study was to investigate the clinical predictive capability of peripheral myeloid dendritic cells (DCs) in Wilms' tumor 1 (WT1) vaccine therapy for patients with gynaecological cancer. Pati...
- Oncogenic KRAS Regulates miR-200c and miR-221/222 in a 3D-Specific Manner in Colorectal Cancer Cells
[作者:Tsunoda, T; Takashima, Y; Yoshida, Y; Doi, K; Tanaka, Y; Fujimoto, T; Machida, T; Ota, T; Koyanagi, M; Kuroki, M; Sasazuki, T; Shirasawa, S,期刊:Anticancer Research, 页码:2453-2459 , 文章类型: Proceedings Paper,,卷期:2011年31-7]
- Background: Oncogenic KRAS plays several key roles in a three-dimensional (3D) colonic-crypt model. However, miRNA expression regulated by oncogenic KRAS in this model is still elusive. Materials and Methods: The differe...
- A Possible Clinical Adaptation of CRM197 in Combination with Conventional Chemotherapeutic Agents for Ovarian Cancer
[作者:Tsujioka, H; Fukami, T; Yotsumoto, F; Ueda, T; Hikita, S; Takahashi, Y; Kondo, H; Kuroki, M; Miyamoto, S,期刊:Anticancer Research, 页码:2461-2465 , 文章类型: Proceedings Paper,,卷期:2011年31-7]
- Aim: Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a promising target for cancer therapy. We have already started a phase 1 study of CRM197, a specific HB-EGF inhibitor, for advanced ovarian canc...
- Functional Characterization of Lipopolysaccharide derived from Symbiotic Bacteria in Rice as a Macrophage-activating Substance
[作者:Kadowaki, T; Inagawa, H; Kohchi, C; Hirashima, M; Soma, GI,期刊:Anticancer Research, 页码:2467-2476 , 文章类型: Proceedings Paper,,卷期:2011年31-7]
- Background and Aim: Lipopolysaccharide derived from a symbiotic bacterium in wheat (Pantoea agglomerans, LPSp) has shown multiple positive effects, such as prophylactic, antiallergic and antitumour effects, without serio...
- Design, Synthesis and Destructive Dynamic Effects of BODIPY-containing and Curcuminoid Boron Tracedrugs for Neutron Dynamic Therapy
[作者:Nakata, E; Koizumi, M; Yamashita, Y; Onaka, K; Sakurai, Y; Kondo, N; Ono, K; Utoi, Y; Hori, H,期刊:Anticancer Research, 页码:2477-2481 , 文章类型: Proceedings Paper,,卷期:2011年31-7]
- Background: We previously designed the boron tracedrugs UTX-42, UTX-43, and UTX-44, which possess antioxidant potency. In order to explore their destructive dynamic effects when bombarded by weak thermal neutrons, we per...
- Antitumor Effects of CRM197, A Specific Inhibitor of HB-EGF, in T-Cell Acute Lymphoblastic Leukemia
[作者:Kunami, N; Yotsumoto, F; Ishitsuka, K; Fukami, T; Odawara, T; Manabe, S; Ishikawa, T; Tamura, K; Kuroki, M; Miyamoto, S,期刊:Anticancer Research, 页码:2483-2488 , 文章类型: Proceedings Paper,,卷期:2011年31-7]
- The therapeutic outcome for T-cell acute lymphoblastic leukemia (T-ALL) remains poor; thus, novel, targeted therapies are urgently needed. Recently, we showed that heparin-binding epidermal growth factor-like growth fact...
- Effect of the Gc-derived Macrophage-activating Factor Precursor (preGcMAF) on Phagocytic Activation of Mouse Peritoneal Macrophages
[作者:Uto, Y; Yamamoto, S; Takeuchi, R; Nakagawa, Y; Hirota, K; Terada, H; Onizuka, S; Nakata, E; Hori, H,期刊:Anticancer Research, 页码:2489-2492 , 文章类型: Proceedings Paper,,卷期:2011年31-7]
- Background: The 1f1f subtype of the Gc protein (Gc(1f1f)protein) was converted into Gc-derived macrophage-activating factor (GcMAF) by enzymatic processing in the presence of beta-galactosidase of an activated B-cell and...
|